Assessing the Ideal Environments in Which Psychedelic Medicines Should Be Administered
Ismail Lourido Ali, JD, director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses which environments each psychedelic medicine is likely to be administered.
Pharmacy Times interviewed Ismail Lourido Ali, JD, director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), on psychedelic medicine policy and current advancements in the field.
During the discussion, Ali addressed which psychedelic drugs have been approved by the FDA for treatment and are either being used as treatments for patients or are planned to be used in the future as approved treatments and what environments each psychedelic medicine is likely to be administered.
